Nikkomycin Z is a
chitin synthetase inhibitor. In vitro,
nikkomycin Z had good activity against Blastomyces dermatitidis, with an MIC of 0.78 microg/ml and a minimal fungicidal concentration of 3.1 microg/ml. The efficacies of various treatment durations (3, 5, or 10 days) and doses (200, 400, or 1,000 mg/kg of
body weight) of
nikkomycin Z given twice daily were compared with those of
itraconazole at 200 mg/kg given twice daily and
amphotericin B at 6.25 mg/kg in a murine model of pulmonary
blastomycosis. All treatments prolonged survival compared with untreated controls (P < 0.05 to 0.01); 100% survival was achieved with 5 or 10 days of any
nikkomycin Z dose or with
amphotericin B.
Amphotericin B and
nikkomycin Z, but not
itraconazole, reduced
infection compared with controls.
Amphotericin B and the 10-day regimens of all
nikkomycin Z doses were equivalent and superior to
itraconazole or
nikkomycin Z for < or = 5 days at any dose (P < 0.05 to 0.01). Increased duration and/or dosage improved the efficacy of
nikkomycin Z, with 10 days of each dose curing 50 to 90% of the animals. Only a 1,000-mg/kg/day dose of
nikkomycin Z was curative when treatment lasted less than 10 days. In contrast,
itraconazole cured no mice, while
amphotericin B cured all mice. Based on the total amount of
drug given,
amphotericin B was estimated to be 32 times as active as
nikkomycin Z and
nikkomycin Z was estimated to be 3 times as active as
itraconazole. Overall,
nikkomycin Z given orally was well tolerated, had good activity against
blastomycosis, and could result in
biological cure, thus producing results equivalent to those of parenteral
amphotericin B.